ASCO 2023: Key Melanoma Studies

CME

Key Studies in Skin Cancer: Independent Conference Coverage of the 2023 ASCO Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 21, 2023

Expiration: August 20, 2024

Activity

Progress
1
Course Completed

Introduction

In this module, Jason Luke, MD, FACP, and Jeffrey Weber, MD, PhD, examine key studies in skin cancer presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Please note that the slide thumbnails in this activity link to a Capsule Summary PowerPoint slideset for each of the studies discussed by Drs Luke and Weber. The Capsule Summary slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with skin cancer do you provide care for in a typical month?

Your 67-year-old patient with high-risk stage IIB melanoma is in your office to discuss adjuvant therapy after surgery. Based on results from the KEYNOTE-716 trial of adjuvant pembrolizumab vs placebo which of the following statements would you tell the patient regarding the efficacy of pembrolizumab?

Which of the following represents the key findings reported from the phase II KEYNOTE-942 trial of an individualized neoantigen mRNA vaccine plus pembrolizumab vs pembrolizumab alone for patients with completely resected, high-risk (stage IIIB-D/IV) melanoma?

Based on recently reported data from the phase I study of fianlimab plus cemiplimab in patients with unresectable or metastatic melanoma, which of the following most accurately describes the patient subgroups that demonstrated a response rate of nearly 45% or better with fianlimab plus cemiplimab?